Rallybio Corporation RLYB on Tuesday shared results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) clinical trial of RLYB116 for complement-mediated diseases, with its initial ...

Innate immunity is a foundational field in immunology, critical for understanding how organisms sense and respond to danger, be it pathogens or sterile ...

Medically reviewed by Michael Menna, DO Complement 3 glomerulopathy is a rare disease caused by a buildup of proteins in the kidneys. The prognosis and life expectancy for C3G depends on the disease ...

In a study, blocking the immune system complement protein C3 was shown to reduce MS disease severity in older mice but not in ...

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

This Rare Disease Day, observed on Feb. 28 worldwide, the American Kidney Fund is committed to improving the understanding of ...